Drugs / BMS-770767
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01058083 | May 2010 → Mar 2011 | hyperlipidemia | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01046422 | May 2010 → Jan 2011 | type 2 diabetes mellitus | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-770767 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01058083 ↗ |
| Route | Oral | “Capsule, Oral, 15mg, Active, Daily, 28 days” NCT01046422 ↗ |